| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 24.05.
| XenneX, BioTime introduce GeneCards version 3.08 | | - | Pharma Bus Review |
| 23.05.
| BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 | | 27 | Business Wire |
| XenneX, a Division of LifeMap Sciences, Inc. and BioTime, Inc. (NYSE
Amex:BTX), announced today the release of GeneCards®, Version
3.08, on May 20, 2012. The new release...
Mehr lesen zu:
BioTime and Subsidiary LifeMap Sciences, Inc. Announce Release of GeneCards® Version 3.08 | |
| 22.05.
| BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases | | 22 | Business Wire |
| BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary
LifeMap Sciences, Inc. has entered into a license agreement with Yeda
Research and Development Company...
Mehr lesen zu:
BioTime and Subsidiary LifeMap Sciences, Inc. Announce Agreement to Market MalaCards - A Database of Human Diseases | |
| 21.05.
| BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. | | 35 | Business Wire |
| BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc.
today announced that they have completed the acquisition of XenneX, Inc.
through a merger of XenneX...
Mehr lesen zu:
BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc. | |
| 18.05.
| BioTime: A Track Record Of Broken Promises | | 2 | Seeking Alpha |
| 23.04.
| BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development | | 37 | Business Wire |
| BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky,
Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide
and update on product development...
Mehr lesen zu:
BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development | |
| 23.04.
| BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen® Product Development | | - | Benzinga.com |
| 23.04.
| BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07 | | 46 | Business Wire |
| BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO
Michael West, Ph.D. will provide and update the development of OTX-CP07
by BioTime's subsidiary OrthoCyte...
Mehr lesen zu:
BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07 | |
| 23.04.
| BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease | | 50 | Business Wire |
| BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler,
Ph.D., Vice President of Research at BioTime's subsidiary ReCyte
Therapeutics, Inc. will provide and...
Mehr lesen zu:
BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease | |
| 23.04.
| BioTime's Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products | | 48 | Business Wire |
| - PanC-Dx on track for CE Marking in Europe by late 2014 -
BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner,
Ph.D., the CEO of BioTime's...
Mehr lesen zu:
BioTime's Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products | |
| 23.04.
| BioTime Provides Update on ReneviaTM Product Development; Product Development on Track for CE Marking by 2013 | | - | Benzinga.com |
| 23.04.
| BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen® Product Development | | 53 | Business Wire |
| - Product development on track for IND filing during 2013 -
BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S. Irving,
Ph.D., the CEO of...
Mehr lesen zu:
BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen® Product Development | |
| 23.04.
| BioTime Provides Update on ReneviaTM Product Development | | 43 | Business Wire |
| - Product development on track for CE Marking by 2013 -
BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D.,
BioTime's Chief Commercial...
Mehr lesen zu:
BioTime Provides Update on ReneviaTM Product Development | |
| 23.04.
| BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells | | 42 | Business Wire |
| - First demonstration of a scalable source of highly purified and
identified progenitor cells capable of making definitive
(non-hypertrophic) cartilage -
...
Mehr lesen zu:
BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells | |
| 20.04.
| BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc. | | 41 | Business Wire |
| Acquisition will integrate GeneCards® and
associated databases in a centralized resource called "LifeMap"
LifeMap Sciences will...
Mehr lesen zu:
BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc. | |
| 18.04.
| BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference | | 37 | Business Wire |
| BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, today announced
that Chief Executive Officer...
Mehr lesen zu:
BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference | |
| 16.04.
| BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012 | | 33 | Business Wire |
| BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops
and markets products in the field of regenerative medicine, today
announced that Chief Executive...
Mehr lesen zu:
BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012 | |
| 16.04.
| Ruling in Texas Could Provide New Opportunities for Stem Cell Companies / Five Star Equities Provides Stock Research on BioTime and Cytori Therapeutics | | 73 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 04/16/12 -- March has shown to be a troublesome month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has fallen over 16 percent in the last month...
Mehr lesen zu:
Ruling in Texas Could Provide New Opportunities for Stem Cell Companies / Five Star Equities Provides Stock Research on BioTime and Cytori Therapeutics | |
| 12.04.
| BioTime Board of Directors Forms Science and Technology Committee | | 35 | Business Wire |
| - Advancing product development efforts -
BioTime, Inc. (NYSE Amex:BTX) today announced that its Board of
Directors has recently formed a Science and...
Mehr lesen zu:
BioTime Board of Directors Forms Science and Technology Committee | |
| 22.03.
| BioTime's Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM | | 29 | Business Wire |
| - An annual PanC-DxTM blood
test could be the future alternative to the mammogram as the frontline
screening method for breast cancer -
BioTime...
Mehr lesen zu:
BioTime's Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM | |
